FCPA Risk in the Healthcare Sector

Healthcare is among the most penalized sectors when it comes to FCPA enforcement. Pharmaceutical, medical supply, and medical technology companies face extensive exposure to government officials due to high volumes of sales to government end-users and a heightened need for regulatory approvals. In addition to these typical FCPA risk factors, the healthcare sector presents unique risks. The DOJ and SEC pursue FCPA cases on the principle that healthcare practitioners (HCPs) in state-run healthcare systems should be considered “foreign officials” subject to the statute’s restrictions.

This extension of the “foreign official” designation creates two related problems. First, the overlap between public and private spheres makes it difficult to determine who such government-connected HCPs are. Second, because HCPs themselves often have multiple affiliations, identifying and mitigating against potential channels of illicit payments can be difficult

PSA has created a brief exploring the challenges that these dynamics present to conducting due diligence on third parties in the healthcare sector.

Download Whitepaper

Explore our
Services

Due Diligence

PSA offers a broad range of due diligence services that are tailored to our clients’ needs and informed by regulatory requirements and relevant guidance.

Investigations

PSA has conducted corporate investigations into issues of embezzlement, fraud, corruption and other misconduct in over 50 countries.

Advisory

PSA provides strategic guidance to firms beyond routine due diligence, crisis-response investigation or market entry advisory services.

Request for a Due Diligence Report

Ready to start a conversation?

Get in touch

Featured Insights

Due Diligence in Saudi Arabia— Pitfalls to Avoid in 2024

Navigate the complex landscape of business transactions in Saudi Arabia with our comprehensive white paper on Due Diligence in the...

LEARN MORE >
Conducting Due Diligence in China

 

For over 15 years PSA’s Shanghai office has been supporting...

LEARN MORE >
Understanding “Abnormal Operations” in China

In 2014, regulations outlining information disclosure requirements for Chinese companies created a List of Companies with Abnormal Operations (“the Abnormal...

LEARN MORE >

How can we help you?

Get in touch with us or inquire with our experts.

Subscribe to receive updates and insights

Better Intelligence Podcast

Copyright © 2022 Pacific Strategies and Assessments | All Rights Reserved